Azithromycin and Septic Shock Outcomes

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Pharmacology

Background:

• Macrolide antibiotics, such as azithromycin, are known for their immunomodulatory effects.
• Limited clinical data exists on the impact of these immunomodulatory properties on measurable outcomes in septic shock.
• Understanding potential benefits of azithromycin in septic shock is crucial for optimizing treatment strategies.

Purpose of the Study:

• To investigate whether empiric antimicrobial regimens including azithromycin can reduce the time to shock resolution in adult patients.
• To evaluate the clinical impact of azithromycin on key outcomes in septic shock patients.

Main Methods:

• Retrospective study of adult patients with septic shock admitted to intensive care units (ICUs) across three urban teaching hospitals.
• Inclusion criteria: norepinephrine requirement for at least 4 hours and at least 48 hours of antimicrobial treatment.
• Propensity score matching was used to compare patients who received azithromycin with those who did not.

Main Results:

• 258 patients were included after propensity score matching (124 in azithromycin group, 134 in control group).
• No significant difference in median shock duration (45.6 hr vs 59.7 hr, P = .44) between groups.
• In-hospital mortality (37.9% vs 38.1%), mechanical ventilation duration, and ICU/hospital length of stay were similar.

Conclusions:

• Empiric use of azithromycin in adult ICU patients with septic shock did not significantly improve shock resolution time.
• Azithromycin did not demonstrate a significant impact on mechanical ventilation duration, ICU length of stay, or hospital length of stay.
• The study did not find a significant effect of empiric azithromycin on in-hospital mortality for septic shock patients.